VISIBLE

VISIBLE is a Wellcome Leap program co-funded with Pivotal Ventures and the British Heart Foundation. It focuses on coronary microvascular disease in women, a condition that current diagnostic pathways often miss, and it sets an unusually explicit target: move effective diagnosis and treatment from under 1 percent to over 80 percent. The 2026 solicitation sat at $55 million. Applications were due on April 23, 2026, and decisions were issued on May 23, 2026. The available record places performers across the United States, the United Kingdom, the Netherlands, Tanzania, and Australia, and the program uses Wellcome Leap's cooperative-agreement model rather than a prize or loan route. The strongest projects are likely to combine cardiovascular medicine with implementation capacity, since the program is built around closing a diagnosis-and-treatment gap at scale. Dr. Birgit Vogel, a cardiologist focused on women's cardiovascular health, directs the program, which points toward teams that can move evidence into delivery rather than stopping at mechanistic insight.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.